Full Press Release Details
Oncolytics Biotech Establishes Scientific Advisory
Board Focused on REOLYSIN Registration Study in Metastatic Breast Cancer
CALGARY and SAN DIEGO, Nov. 30, 2017 /CNW/ - Oncolytics Biotech
Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN , also known as
pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold'
tumors 'hot', today announced the establishment of its Scientific Advisory Board (SAB). The SAB will provide Oncolytics with
significant clinical expertise and experience in breast cancer drug development in both the U.S. and Europe with the following
"As we continue to expand our collaborative third-party
expertise to build on the momentum of our phase 3 program in metastatic breast cancer, we are delighted to introduce a strong Scientific
Advisory Board comprised of world-renowned clinical and medical oncologists," said Dr. Matt Coffey, President and CEO of Oncolytics
Biotech. "Drs. Piccart, Prat and Sharma will provide crucial guidance based on their specializations in breast cancer drug
development and cancer immunotherapy, which parallel the development plan we have established for REOLYSIN."
Dr. Mattine Piccart is a Professor of Oncology at the Universit
Libre de Bruxelles and a member of the Breast Cancer Research Foundation (BCRF) SAB. She is a member of the European Society of
Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale Working Group and co-founder and Chair of the Breast International
Group (BIG), an international group that includes more than 56 cooperative groups, more than 10,000 experts and links more than
3,000 hospitals. Dr. Piccart was President of ESMO from 2012 to 2013 and the European Cancer Organization (ECCO) from 2014 to 2015.
She is a former president of the European Organisation for Research and Treatment of Cancer (EORTC) and served on the American
Society of Clinical Oncology (ASCO) Board. Author or co-author of more than 470 peer-reviewed publications, she has received numerous
prestigious awards, including the Jill Rose Award, the William L. McGuire Award, the Umberto Veronesi Award for the Future Fight
against Cancer, and 2013 David A. Karnofsky Memorial Award, Dr. Piccart obtained both her M.D. and Ph.D. degrees from the Universit
Dr. Aleix Prat is the Head of Medical Oncology of the Hospital
Clinic of Barcelona, Associate Professor of the University of Barcelona and the Head of the Translational Genomics and Targeted
Therapeutics in Solid Tumors Group at August Pi i Sunyer Biomedical Research Institute (IDIBAPS). Dr. Prat designs and leads clinical
trials for novel drugs and approaches, and has a particular interest in the clinical implications of different subtypes of breast
cancer. He is currently the scientific coordinator of SOLTI, a Spanish breast cancer cooperative group, and was recently named
as a Member of the Executive Committee of BIG. In 2008, Dr. Prat became a postdoctoral research associate at the Lineberger Comprehensive
Cancer Center (University of North Carolina), and in 2012, returned to Barcelona as the Head of the Translational Genomics Group
at Vall d Hebron Institute of Oncology (VHIO). Dr. Prat obtained his M.D. degree in 2003 from the University of Barcelona
and completed a medical oncology fellowship in 2008 at VHIO.
At the University of Texas MD Anderson Cancer Center, Dr.
Padmanee Sharma is a Professor at the Department of Genitourinary Medical Oncology, the Co-Director of the Parker Institute for
Cancer Immunotherapy and Scientific Director of the Immunotherapy Platform at the Department of Immunology. She has participated
in 54 research outputs since 1996, focusing primarily on immunotherapy, and is principal investigator of several immunotherapy
clinical trials that study immune and anti-tumor responses in cancer patients. Dr. Sharma has served as a member of the BMS Immuno-Oncology
Network, a Member of the SAB at Kite Pharma, Inc. and also recently became a member of Constellation Pharmaceuticals, Inc.'s SAB.
Dr. Sharma holds a Ph.D. in immunology and an M.D. from Pennsylvania State University.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing REOLYSIN, also known as pelareorep, an intravenously delivered immuno-oncolytic
virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype - turning 'cold' tumors 'hot'
- through innate and adaptive immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes
three pillars: chemotherapy combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune
responses; and immune modulator (IMiD) combinations to facilitate innate immune responses. Oncolytics is currently planning
its first registration study in metastatic breast cancer, as well as studies in combination with checkpoint inhibitors and targeted
and IMiD therapies in solid and hematological malignancies. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable
Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as
"forward-looking statements"). Forward-looking statements, including the Company's belief as to the potential of REOLYSIN
as a cancer therapeutic; the anticipated benefits of the formation of the Scientific Advisory Board to the Company; the composition
of the Scientific Advisory Board; the Company's plans regarding its first registration study in metastatic breast cancer and studies
in combination with checkpoint inhibitors and IMiD therapies in solid and hematological malignancies; and other statements related
to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which
could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties
include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN
as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully
commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the
regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual
filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does
not undertake to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
View original content: http://www.newswire.ca/en/releases/archive/November2017/30/c5768.html
For further information: Investor Relations & Company
Contact: Michael Moore, Vice President, Investor Relations & Corporate Communications, 858-886-7813, mmoore@oncolytics.ca;
Media Contact: Mark Corbae, Canale Communications, 619-849-5375, mark@canalecomm.com
CO: Oncolytics Biotech Inc.
CNW 07:00e 30-NOV-17